Meet us at Growth Asia Summit July 8-10 in Singapore. Here we look forward to exploring the latest market opportunities that have emerged in Asia.
We will be in Taipei from July 15-19, showcasing the science behind LP299V® for sports performance and HEAL9® for mental health and cognitive support. Visit us in Hall 1, Booth I304, 1F.
On 20 November 2024, Probi AB’s (“Probi”) principal shareholder and parent company Symrise AG (“Symrise”) announced that Symrise is making a public takeover offer to the shareholders of Probi for SEK 350 per Probi share (the “Offer”). The acceptance period for the Offer is expected to commence on 18 December 2024 and end on or about 15 January 2025.
Read more on Symrise’s website, www.symrise.com/de/probi.
Probi’s Board comments on Symrise’s public takeover offer
Probi applies for delisting and convenes an Extraordinary General Meeting
